



RECEIVED

MAY 02 2002

TECH CENTER 1600/2900

A¹

residues 230-345 of SEQ ID NO:2;
residues 231-345 of SEQ ID NO:2;
residues 232-345 of SEQ ID NO:2;
residues 233-345 of SEQ ID NO:2;
residues 234-345 of SEQ ID NO:2;
residues 235-345 of SEQ ID NO:2;
residues 236-345 of SEQ ID NO:2;
residues 237-345 of SEQ ID NO:2;
residues 238-345 of SEQ ID NO:2;
residues 239-345 of SEQ ID NO:2; and
residues 240-345 of SEQ ID NO:2.

COPY OF PAPERS
ORIGINALLY FILED

A²

9. (amended) The method of claim 1 wherein the antibody is a monoclonal antibody.

A³

11. (amended) A method of treating fibrosis in a mammal comprising administering to the mammal a composition comprising a therapeutically effective amount of a zveg3 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zveg3 antagonist is an antibody that specifically binds to a dimeric protein having two polypeptide chains, wherein each of said polypeptide chains consists of a sequence of amino acid residues selected from the group consisting of:

residues 230-345 of SEQ ID NO:2;
residues 231-345 of SEQ ID NO:2;
residues 232-345 of SEQ ID NO:2;
residues 233-345 of SEQ ID NO:2;
residues 234-345 of SEQ ID NO:2;
residues 235-345 of SEQ ID NO:2;
residues 236-345 of SEQ ID NO:2;
residues 237-345 of SEQ ID NO:2;
residues 238-345 of SEQ ID NO:2;
residues 239-345 of SEQ ID NO:2; and
residues 240-345 of SEQ ID NO:2.

A⁴

15. (amended) The method of claim 11 wherein the antibody is a monoclonal antibody.

17. (amended) A method of reducing stellate cell activation in a mammal comprising administering to the mammal a composition comprising a zveg3 antagonist in combination with a pharmaceutically acceptable delivery vehicle, in an amount sufficient to reduce stellate cell activation, wherein the zveg3 antagonist is an antibody that specifically binds to a dimeric protein having two polypeptide chains, wherein each of said polypeptide chains consists of a sequence of amino acid residues selected from the group consisting of:

residues 230-345 of SEQ ID NO:2;
 residues 231-345 of SEQ ID NO:2;
 residues 232-345 of SEQ ID NO:2;
 residues 233-345 of SEQ ID NO:2;
 residues 234-345 of SEQ ID NO:2;
 residues 235-345 of SEQ ID NO:2;
 residues 236-345 of SEQ ID NO:2;
 residues 237-345 of SEQ ID NO:2;
 residues 238-345 of SEQ ID NO:2;
 residues 239-345 of SEQ ID NO:2; and
 residues 240-345 of SEQ ID NO:2.

Please cancel claims 7, 8, 10, 14, and 16 without prejudice.

Please add the following new claims:

19. The method of claim 17 wherein the antibody is a monoclonal antibody.
20. The method of claim 17 wherein the antibody is a single-chain antibody.
21. The method of claim 17 wherein the antibody is a humanized antibody.
22. The method of claim 1 wherein the antibody is a single-chain antibody.
23. The method of claim 1 wherein the antibody is a humanized antibody.